Algert Global LLC Has $1.74 Million Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Algert Global LLC lowered its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 5.0% in the second quarter, Holdings Channel.com reports. The fund owned 40,256 shares of the biopharmaceutical company’s stock after selling 2,110 shares during the period. Algert Global LLC’s holdings in Agios Pharmaceuticals were worth $1,736,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AGIO. Acadian Asset Management LLC bought a new position in Agios Pharmaceuticals during the 2nd quarter valued at about $37,000. Quest Partners LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth about $40,000. NEOS Investment Management LLC acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $210,000. North Star Asset Management Inc. bought a new stake in Agios Pharmaceuticals in the second quarter valued at approximately $216,000. Finally, XTX Topco Ltd bought a new position in Agios Pharmaceuticals during the second quarter worth about $230,000.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AGIO. Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the company from $60.00 to $56.00 in a research report on Friday, September 27th. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and a consensus target price of $52.50.

Agios Pharmaceuticals Stock Performance

AGIO opened at $40.56 on Friday. The firm has a market cap of $2.30 billion, a P/E ratio of -6.51 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a fifty-two week low of $19.80 and a fifty-two week high of $53.28. The firm has a 50-day moving average of $45.34 and a 200 day moving average of $40.02.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The company had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. During the same period in the previous year, the company earned ($1.51) EPS. Agios Pharmaceuticals’s quarterly revenue was up 28.4% on a year-over-year basis. Equities research analysts predict that Agios Pharmaceuticals, Inc. will post -4.85 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. The disclosure for this sale can be found here. Insiders own 4.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.